WINT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
WINT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:
We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.
Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.
As of today (2024-04-25), Windtree Therapeutics's share price is $5.155. Windtree Therapeutics's GF Value is $0.11. Therefore, Windtree Therapeutics's Price-to-GF-Value for today is 46.86.
Based on the relationship between the current stock price and the GF Value, GuruFocus believes Windtree Therapeutics is Significantly Overvalued.
Windtree Therapeutics (NAS:WINT) GF Value Explanation
Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:
Posssible Evaluations | All-in-One Screener Examples (2) |
Possible Value Trap, Think Twice (1) | Predictable Companies that possibly be Value Traps |
Significantly Overvalued | Predictable Companies which are Significantly Overvalued |
Modestly Overvalued | Predictable Companies which are Modestly Overvalued |
Fairly Valued | Predictable High Quality Companies which are Fairly Valued |
Modestly Undervalued (3) | Predictable High Quality Companies which are Modestly Undervalued |
Significantly Undervalued (3) | Predictable High Quality Companies which are Significantly Undervalued |
(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.
(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.
(3) There is only a sufficient margin of safety when the stock is undervalued.
Windtree Therapeutics's Price-to-GF-Value for today is calculated as
Price-to-GF-Value | = | Share Price | / | GF Value |
= | 5.155 | / | 0.11 | |
= | 46.86 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Windtree Therapeutics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Craig Fraser | director, officer: Chief Executive Officer | AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142 |
Jamie Mcandrew | officer: VP, Controller, & CAO | WINDTREE THERAPEUTICS, INC., 2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976 |
Mark Strobeck | director | 460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087 |
James Huang | director | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
John P. Hamill | officer: SVP & CFO | 4092 NEW HOPE ROAD, FURLONG PA 18925 |
Bioengine Capital Inc. | 10 percent owner | 7 F., NO. 3-2, PARK ST., NANGANG DIST., TAIPEI F5 11503 |
Center Laboratories, Inc. | 10 percent owner | 7 ., NO. 3-2, PARK ST. NANGANG DIST., TAIPEI F5 11503 |
Diane Carman | officer: SVP & General Counsel | 2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976 |
Eric Curtis | officer: SVP & COO | ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142 |
Steven Simonson | officer: SVP, Chief Development Officer | 2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976 |
Evan Loh | director | 75 KNEELAND STREET, BOSTON MA 02111 |
Leslie J. Williams | director | C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730 |
Robert A Scott | director | |
Joseph M Mahady | director | 16640 CHESTERFIELD GROVE RD, SUITE 200, CHESTERFIELD MO 63005 |
Brian D Schreiber | director | 2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976 |
From GuruFocus
By Marketwired • 10-10-2023
By sperokesalga sperokesalga • 04-27-2023
By sperokesalga sperokesalga • 06-05-2023
By ACCESSWIRE • 01-18-2024
By sperokesalga sperokesalga • 05-15-2023
By sperokesalga sperokesalga • 02-28-2023
By ACCESSWIRE • 07-18-2023
By Marketwired • 10-03-2023
By Marketwired • 08-07-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.